![]() |
Gastric Cancer |
Free Subscription
1 Anticancer Res |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Gastric Cancer is free of charge.
In-hospital Outcomes Between Total Parenteral Nutrition and Enteral Feeding in
Esophageal and Gastric Cancer: A Nationwide Analysis.
Anticancer Res. 2025;45:2453-2457.
PubMed
Abstract available
Clinical benefit of continuation of PD-1 inhibitors after progression on
first-line chemoimmunotherapy in metastatic gastric cancer and biomarker
exploration.
BMC Cancer. 2025;25:935.
PubMed
Abstract available
Comprehensive analysis of risk factors and nomogram development for predicting
hepatic metastasis following radical resection of adenocarcinoma of the
esophagogastric junction.
BMC Gastroenterol. 2025;25:409.
PubMed
Abstract available
Harnessing exosomes: From tumor immune escape to therapeutic innovation in
gastric cancer immunotherapy.
Cancer Lett. 2025;626:217792.
PubMed
Abstract available
Management of peritoneal gastric metastasis: An update.
Eur J Surg Oncol. 2025;51:109731.
PubMed
Abstract available
Diagnostic performance of fluorescent lymphography-guided lymph node dissection
during minimally invasive gastrectomy following chemotherapy.
Eur J Surg Oncol. 2025;51:109738.
PubMed
Abstract available
Textbook outcome and textbook oncological outcome in esophagogastric cancer
surgery - A systematic scoping review.
Eur J Surg Oncol. 2025;51:109672.
PubMed
Abstract available
Gastric Cancer Prevention in the United States: A Work in Progress.
Gastroenterology. 2025 May 21:S0016-5085(25)00769.
PubMed
Impact of prognostic nutritional index on oncological outcomes and mortality
among advanced gastric cancer patients: European GASTRODATA registry analysis.
Int J Cancer. 2025 May 28. doi: 10.1002/ijc.35489.
PubMed
Abstract available
Adjuvant chemotherapy may have no significant survival benefit in older patients
with stage II/III gastric cancer: a multicenter retrospective study.
J Cancer Res Clin Oncol. 2025;151:175.
PubMed
Abstract available
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in
Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.
J Clin Oncol. 2025 May 23:JCO2401119. doi: 10.1200/JCO.24.01119.
PubMed
Abstract available
Endogenous and extracellular roles of a tumor suppressor miR-379-5p in gastric
cancer.
Oncology. 2025 May 26:1-16. doi: 10.1159/000546620.
PubMed
Abstract available
Thank you for your interest in scientific medicine.